Mdxhealth to Release Third Quarter 2026 Financial Results on November 12

Mdxhealth (MDXH) will release its third-quarter 2026 financial results after market close on November 12, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Mdxhealth (MDXH) will release its third-quarter 2026 financial results after market close on November 12, 2026. The results cover the quarter ended September 30, 2026.

A conference call and webcast with live questions and answers will follow at 4:30pm ET / 22:30 CET. A webcast replay will be available on the company’s website after the call.

Key Terms

genomic, epigenomic, exosomal

3 terms

genomic technical

"proprietary genomic, epigenomic, exosomal and other molecular technologies"

Relating to an organism’s genome — the complete set of DNA instructions that determine traits and biological functions — and to the study or use of that information. For investors, genomic technologies and data underpin diagnostics, targeted medicines, and personalized treatments, shaping potential market size, product timelines, and regulatory risk; think of it as reading an instruction manual to design precise medical products, which can speed innovation but also bring scientific and approval uncertainty.

epigenomic technical

"proprietary genomic, epigenomic, exosomal and other molecular technologies"

The epigenomic describes the pattern of chemical tags and markers across a cell’s DNA that control which genes are turned on or off, like sticky notes on a recipe book guiding what gets cooked. For investors, epigenomic changes are important because they can reveal new drug targets, diagnostics, or ways to predict and treat disease, affecting a biotech’s product pipeline, regulatory path, and long-term market value.

exosomal technical

"proprietary genomic, epigenomic, exosomal and other molecular technologies"

Describing something derived from or related to exosomes — tiny packets cells naturally release to send signals and carry molecules like proteins, RNA or lipids to other cells. For investors, “exosomal” flags technologies or products that use these biological packets for diagnostics, drug delivery or disease monitoring, which can promise more precise tests or therapies but also face scientific, manufacturing and regulatory hurdles. Think of exosomes as biological mail carriers and “exosomal” as anything that uses or studies that mail.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2026 - 04:00 PM EDT

Company to Host Conference Call with Live Q&A, November 12, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – October 29, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2026, after market close on Thursday, November 12, 2026.

Title:	Mdxhealth Presents Third Quarter 2026 Financial Results and Corporate Update Conference Call and Webcast
Date:	November 12, 2026
Time:	4:30pm ET/ 22:30 CET
Conference Call Dial-in Details:	United States: 1-800-347-6865 Belgium: 08 007 2519 United Kingdom: 0808 101 1183
Conference ID:	MDX3Q26
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1778654&tp_key=d6263296bf

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

info@mdxhealth.com

LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
jfraunces@lifesciadvisors.com